Sionna Therapeutics (SION) Liabilities and Shareholders Equity (2024 - 2026)

Sionna Therapeutics has reported Liabilities and Shareholders Equity for 3 years, with the latest figure at $305.0 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 17.48% year-over-year to $305.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 138.07% YoY) and the FY2025 annual result came in at $326.0 million, up 75.48% from the prior year.
• Liabilities and Shareholders Equity slipped to $305.0 million in Q1 2026 per SION's latest filing, from $326.0 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $369.7 million in Q1 2025 and troughed at $185.8 million in Q4 2024.
• A 3-year average of $313.0 million and a median of $332.6 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2025 and 2026: Liabilities and Shareholders Equity surged 75.48% in 2025, then slipped 17.48% in 2026.
• Over 3 years, Liabilities and Shareholders Equity stood at $185.8 million in 2024, then soared by 75.48% to $326.0 million in 2025, then dropped by 6.42% to $305.0 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $305.0 million, $326.0 million, and $339.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.